与复发性复发性硬化症患者的其他高效疗法相比,纳塔利祖马布的成本后果分析
Luca Prosperini1, Vincenzo Brescia Brescia Morra2,3, Carla Fornari4
1Department of Neurosciences, MS Centre, S. Camillo-Forlanini Hospital, Rome, Italy.
PharmacoEconomics
|September 19, 2025
概括
纳塔利祖马布是一种高度有效的复发性复发性多发性硬化症 (RRMS) 治疗方法,其临床结果与其他疾病修饰疗法 (DMT) 相似,但具有显著的成本节约. 新的皮下注射配方进一步减少了注射时间和成本.
科学领域:
- 药物经济学 药物经济学
- 神经学 神经学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 对复发性缓解性多发性硬化症 (RRMS) 的高效疾病修饰治疗 (DMT) 的日益使用,需要进行比较价值评估.
- 优化治疗方案引发了有关现有疗法的相对成本效益的问题.
研究的目的:
- 评估纳塔利祖马布与意大利其他高效的DMT相比的成本效益.
- 评估皮下与静脉注射纳塔利祖马布对RRMS患者时间和成本的影响.
主要方法:
- 从意大利国家卫生服务和社会角度进行了成本后果分析.
- 马尔科夫模型模拟了纳塔利祖马布,奥法图穆马布和奥克雷祖马布的临床和成本结果.
- 两种情景比较了延长剂量纳塔利祖马布治疗方案和给药途径 (静脉 vs 皮下注射).
主要成果:
- 纳塔利祖马布表现出类似的临床和社会结果,疾病进展和质量调整后寿命年数略有改善.
- 与ocrelizumab和ofatumumab相比,natalizumab在5年内实现了统计学上显著的成本降低.
- 与静脉注射形式相比,皮下纳塔利祖马布降低了资源消耗,注射时间和成本,从而大大节省了5年的成本.
结论:
- 6周的纳塔利祖马布治疗方案在5年内提供了轻微的临床/社会效益和相对于ocrelizumab和ofatumumab的显著成本降低.
- 皮下施用纳塔利祖马布与减少施用时间和成本有关.
- 纳塔利祖马布代表了管理RRMS的成本效益选择,配方改进提高了效率.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
151
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
151
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
179
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
179
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
216
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
216
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
153
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
153